ABSI News and Press, Absci Corporation From 06/06/23

VANCOUVER, Wash., June 06, 2023 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a generative AI drug creation company, today announced the appointment of Frans van Houten to its Board of Directors. With his exceptional leadership experience and deep industry knowledge in the healthcare and tech...

2023-05-25 10:04:19 ET Gainers: Absci ( ABSI ) +17% . Predictive Oncology ( POAI ) +10% . Cardio Diagnostics ( CDIO ) +8% . Ocean Biomedical ( OCEA ) +8% . HeartBeam ( BEAT ) +7% . Losers: Annexon ( ANNX ) -57% .&#...

2023-05-22 12:55:14 ET Gainers: Microbot Medical  ( MBOT ) +132% . Greenhill & Co ( GHL ) +117% . Hepion Pharmaceuticals ( HEPA ) +64% . Akebia Therapeutics ( AKBA ) +39% . VectivBio Holding ( VECT ) +36% . Atea Phar...

2023-05-15 17:20:48 ET Absci press release ( NASDAQ: ABSI ): Q1 GAAP EPS of -$0.26. Revenue of $1.3M (+62.5% Y/Y). For further details see: Absci GAAP EPS of -$0.26, revenue of $1.3M

Commenced work plan preparations and expect to initiate program work during second quarter leveraging Absci's generative AI drug creation platform for Phase II candidate Achieved rapid advancements of generative AI drug creation platform, continually building on prior breakthroughs ...

VANCOUVER, Wash. and OXFORD, UK, May 11, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, and the University of Oxford’s Kennedy Institute of Rheumatology , a biomedical research center developing new therapies for chronic in...

VANCOUVER, Wash. and NEW YORK, April 06, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcoming 22 nd Annual Needham Virtual Healthcare Conference. Absci management is scheduled ...

2023-04-04 11:58:02 ET Absci Corp ( NASDAQ: ABSI ) has partnered with M2GEN to develop new cancer medicines more rapidly than is currently done. Absci's ( ABSI ) artificial intelligence drug creation platform will use  M2GEN's clinical and molecular data set, OR...

VANCOUVER, Wash. and TAMPA, Fla., April 04, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, and M2GEN , an oncology bioinformatics company with the most advanced lifetime-consented clinicogenomics data to accelerate discovery resea...

2023-04-01 10:00:00 ET Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports a...